Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

(High)

(Very Positive)

Rhea-AI Summary

Northwest Biotherapeutics (OTCQB:NWBO) announced that Chief Technical Officer Dr. Marnix Bosch will present “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses” at the 2026 British Neuro-Oncology Society meeting on July 3 at 10:00 a.m. GMT.

The talk will address DCVax-L treatment and patient survival using propensity score matching. A slide deck will be posted on the company’s website. Northwest Biotherapeutics is developing DCVax-L for glioblastoma, supported by a completed 331-patient Phase III trial, JAMA Oncology publication, and a UK marketing authorization application under review.

News Market Reaction – NWBO

+1.20%

+1.20% Session close to close

In the Jul 2 session, NWBO gained 1.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/02/2026 - 02:17 PM

BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The presentation is scheduled for Friday, July 3, at 10:00 a.m. GMT, and will address the association between DCVax-L treatment and patient survival using propensity score matching methodologies (PSM). The slide deck will be posted on the Northwest Biotherapeutics website after Dr. Bosch's presentation.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax^® dendritic cell-based vaccines. The Company's lead program involves DCVax^®-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax^®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning plans for DCVax^® are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will be viewed as demonstrating safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS
Northwest Biotherapeutics
Dave Innes	George Zavoico
804-513-4758	203-644-8083
dinnes@nwbio.com	gzavoica@nwbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-scientific-presentation-on-propensity-score-matching-at-the-british-neuro-oncology-society-annual-meeting-302817146.html

SOURCE Northwest Biotherapeutics, Inc.

FAQ

What will Northwest Biotherapeutics (OTCQB:NWBO) present at the 2026 BNOS annual meeting?

Northwest Biotherapeutics will present a study titled “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses.” According to Northwest Biotherapeutics, the presentation examines associations between DCVax-L treatment and patient survival using propensity score matching methodologies at the 2026 British Neuro-Oncology Society annual meeting.

When is the Northwest Biotherapeutics DCVax-L propensity score matching presentation at BNOS 2026?

The DCVax-L propensity score matching presentation is scheduled for Friday, July 3, 2026, at 10:00 a.m. GMT. According to Northwest Biotherapeutics, Dr. Marnix Bosch, the company’s Chief Technical Officer, will deliver the scientific talk at the British Neuro-Oncology Society annual meeting.

What is DCVax-L from Northwest Biotherapeutics (NWBO) and what trials have been completed?

DCVax-L is a dendritic cell-based personalized immunotherapy for glioblastoma. According to Northwest Biotherapeutics, a 331-patient Phase III trial in glioblastoma has been completed, with results presented at scientific meetings and published in JAMA Oncology, supporting further regulatory review activities.

What is the UK regulatory status of DCVax-L from Northwest Biotherapeutics as of July 2026?

DCVax-L has a marketing authorization application under review in the UK. According to Northwest Biotherapeutics, the application seeks commercial approval for DCVax-L in glioblastoma following completion of a 331-patient Phase III trial and publication of trial results in JAMA Oncology.

What is DCVax-Direct and what are Northwest Biotherapeutics’ next clinical plans?

DCVax-Direct is a personalized immunotherapy candidate for inoperable solid tumor cancers. According to Northwest Biotherapeutics, a 40-patient Phase I trial has been completed, and the company plans to pursue Phase II trials during the current year to further evaluate this dendritic cell-based platform.

Has Northwest Biotherapeutics tested DCVax-L outside glioblastoma indications?

Yes, DCVax-L has been studied in advanced ovarian cancer. According to Northwest Biotherapeutics, a Phase I/II trial in advanced ovarian cancer was previously conducted in collaboration with the University of Pennsylvania, reflecting broader exploration of its DCVax dendritic cell vaccine platform.